Review
Gastroenterology & Hepatology
Michael N. Rosen, Rachel A. Goodwin, Michael M. Vickers
Summary: Pancreatic cancer is a deadly disease, especially for patients with BRCA mutations. These mutation carriers have some effective treatment options, including platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Yong Jae Lee, Myong Cheol Lim, Byoung Gie Kim, Natalie Yl Ngoi, Chel Hun Choi, Sang Yoon Park, David S. P. Tan, Yunjung Go, Jung Yun Lee
Summary: This study aims to investigate if the addition of pembrolizumab and bevacizumab to olaparib maintenance can improve progression-free survival in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Mitchell S. Anscher, Elaine Chang, Xin Gao, Yutao Gong, Chana Weinstock, Erik Bloomquist, Oluseyi Adeniyi, Rosane Charlab, Sarah Zimmerman, Maritsa Serlemitsos-Day, Yang Min Ning, Ruth Mayrosh, Barbara Fuller, Ann Marie Trentacosti, Pamela Gallagher, Karen Bijwaard, Reena Philip, Soma Ghosh, Frances Fahnbulleh, Felicia Diggs, Shaily Arora, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur, Amna Ibrahim, Julia A. Beaver
Summary: The FDA granted accelerated approval to rucaparib for the treatment of adult patients with deleterious BRCA mutation-associated mCRPC in May 2020, based on positive data from the TRITON2 trial. The drug demonstrated a high objective response rate and acceptable toxicity profile, with ongoing clinical benefit verification through the TRITON3 trial.
Review
Oncology
Ximu Sun, Xin Wang, Jie Zhang, Zhixia Zhao, Xin Feng, Lihong Liu, Zhuo Ma
Summary: PARP inhibitors significantly improved progression-free survival and overall survival in patients with BRCA-mutated advanced breast cancer, with tolerable safety and improved quality of life.
Article
Oncology
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J. Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A. Ledermann, Ursula A. Matulonis, Amit M. Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L. Scott, Werner Meier, Ronnie Shapira-Frommer, Tsveta Milenkova, Eric Pujade-Lauraine, Val Gebski, Chee K. Lee
Summary: A prognostic nomogram was developed to predict PFS in patients with BRCA mutations and PSROC, consisting of predictors including CA-125, platinum free interval, presence of measurable disease, and number of prior lines of platinum therapy. The nomogram showed good discrimination and calibration in validation cohorts.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Mingyang Zhang, Xinshuang Yu, Jianguo Wang, Yongxiang Li, Lili Cao
Summary: This meta-analysis evaluated the efficacy of PARP inhibitors in treating BRCA-mutated breast cancer, finding that both combined therapy and monotherapy with PARPi significantly extended progression-free survival compared to standard chemotherapy, with slightly higher hematological toxicity but better overall safety and tolerance.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2021)
Article
Oncology
Yves Pommier, Anish Thomas
Summary: ADCs are effective in delivering cytotoxic agents to tumors, and two ADCs delivering TOP1 poisons have been FDA-approved. A recent study introduced a TOP1-anti B7-H4 ADC that showed synergistic effect with a PARP1-selective inhibitor.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen
Summary: YHP-836, a novel PARP inhibitor, demonstrates excellent inhibitory activity for both PARP1 and PARP2 enzymes and allosterically regulates them via DNA trapping. It shows cytotoxicity and induces cell cycle arrest in BRCA-mutated tumor cell lines, as well as sensitizes tumor cells to chemotherapy agents.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Gastroenterology & Hepatology
Joaquina Martinez-Galan, Isabel Rodriguez, Octavio Caba
Summary: Pancreatic cancer remains as one of the most aggressive cancers with limited improvements in survival rates. However, patients with mutant BRCA gene may have better responses to platinum-based chemotherapy, and maintenance treatment with PARP inhibitors could improve progression-free survival for these patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Cell Biology
Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang, Xiaowei Qi
Summary: The study compared the efficacy and safety of talazoparib and olaparib in patients with BRCA-mutated HER2-negative metastatic or advanced breast cancer, showing similar performance in efficacy and safety, but olaparib had lower risk of anemia and neutropenia compared to talazoparib.
Review
Pharmacology & Pharmacy
Qin Xu, Zhengyu Li
Summary: PARPi has become a crucial maintenance therapy for ovarian cancer, especially in non-BRCA mutated population. However, the lack of unified HRD status detection methods poses a challenge and further research is needed.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Kasper Fugger, Ilirjana Bajrami, Mariana Silva Dos Santos, Sarah Jane Young, Simone Kunzelmann, Geoff Kelly, Graeme Hewitt, Harshil Patel, Robert Goldstone, Thomas Carell, Simon J. Boulton, James MacRae, Ian A. Taylor, Stephen C. West
Summary: Mutations in BRCA1 or BRCA2 genes increase the risk of breast and ovarian cancer, but inhibiting DNPH1 can enhance the sensitivity of BRCA-deficient cells to PARP inhibitors. Targeting DNPH1 provides a promising strategy for hypersensitizing BRCA-deficient cancers to PARPi therapy.
Article
Oncology
Xiao-Feng Xie, Nan-Qiang Wu, Jin-Feng Wu, Guang-Lin Zhang, Jin-Feng Guo, Xue-Lian Chen, Cai-Wen Du
Summary: The combination of PARP inhibitor and CXCR4 inhibitor shows enhanced anti-tumor effect in BRCA-proficient triple-negative breast cancer, potentially broadening the indication of PARP inhibitors for this patient population.
Article
Multidisciplinary Sciences
Maria Laura Kevorkian, Salome C. Vilchez Larrea, Silvia H. Fernandez Villamil
Summary: This study identifies the nuclear localization of TcPARP and its enrichment in the nucleolus of Trypanosoma cruzi. The study also reveals the presence of TcPARP in a thread-like structure connecting two dividing nuclei, and the detection of ADP-ribose polymers in this structure during mitosis. These findings shed light on new potential functions of TcPARP inside the nucleus and contribute to our understanding of its role in trypanosomatids beyond the well-described DNA damage response.
Review
Biochemistry & Molecular Biology
Palmiro Poltronieri, Masanao Miwa, Mitsuko Masutani
Summary: ADP-ribosylation plays a crucial role in post-translational modifications of proteins, involving functions such as DNA repair, transcription, and cell signaling. Enzymes involved in monoADP-ribosylation/polyADP-ribosylation (MAR/PAR) cycling also play important roles in cancers, with potential applications in non-oncological diseases. The field is still actively uncovering novel enzymes at a rapid pace.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
